Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study

This randomized, real-life, single-center clinical trial aims to compare the efficacy and safety of probiotic Clostridium butyricum CBM588® (Butirrisan®) versus Rifaximin in the management of Symptomatic Uncomplicated Diverticular Disease (SUDD). Patients with diverticulosis and a history of mild-to-moderate diverticulitis will be randomized into two treatment groups: Experimental Group: Clostridium butyricum CBM588® (Butirrisan®) + fiber supplementation Control Group: Rifaximin + fiber supplementation The primary endpoint is the reduction in SUDD symptoms, assessed over a 12-month treatment period using patient-reported questionnaires. Secondary outcomes include safety evaluation, risk of surgery, and changes in abdominal pain frequency and severity.